Financial Performance - The company's revenue for Q1 2024 was ¥169,415,280.79, a decrease of 9.93% compared to ¥188,099,341.58 in the same period last year[4] - Net profit attributable to shareholders was ¥436,078.05, down 94.74% from ¥8,296,526.04 year-on-year[4] - The company reported a net loss of CNY 1,995,542.87 for Q1 2024, compared to a net profit of CNY 6,599,441.00 in Q1 2023[24] - The company incurred a total comprehensive loss of CNY 1,995,542.87 for Q1 2024, compared to a comprehensive income of CNY 6,599,441.00 in the previous year[24] - Earnings per share for Q1 2024 were CNY 0.0028, a decrease from CNY 0.0526 in Q1 2023[24] Cash Flow and Assets - The net cash flow from operating activities was -¥21,959,297.71, a decline of 629.81% compared to ¥4,144,778.54 in the previous year[4] - Operating cash flow for Q1 2024 was negative at CNY -21,959,297.71, a significant decline from CNY 4,144,778.54 in the same period last year[26] - The company's total assets decreased by 4.23% to ¥1,058,257,247.64 from ¥1,105,053,620.18 at the end of the previous year[4] - The company's total current assets decreased from CNY 657.09 million at the beginning of the period to CNY 594.13 million at the end of Q1 2024[20] - Cash and cash equivalents dropped from CNY 115.32 million to CNY 65.80 million during the same period[20] - Cash and cash equivalents at the end of Q1 2024 were CNY 58,559,984.04, down from CNY 60,430,281.75 at the end of Q1 2023[26] Liabilities and Equity - Total liabilities decreased from CNY 398.04 million to CNY 353.24 million, a reduction of approximately 11.25%[21] - The company’s total equity attributable to shareholders rose slightly to CNY 689,205,541.50 from CNY 688,769,463.45[22] Research and Development - Research and development expenses increased by 69.07% year-on-year, primarily due to higher personnel costs[7] - Research and development expenses increased to CNY 4,101,953.76, up 69.3% from CNY 2,426,194.66 in Q1 2023, indicating a focus on innovation[23] Investment and Income - Investment income surged by 19,345.21% due to the change in accounting treatment of a subsidiary to an associate[9] - The company reported a 90.82% decrease in non-operating income, primarily due to last year's acquisition-related income[11] Organizational Changes and Strategy - The company restructured its organizational framework to enhance brand operations, establishing dedicated operational teams for various brands[17] - The company is focusing on diversifying sales channels through a combination of online and offline strategies, including live streaming and multi-brand stores[17] - The company transitioned Klattermusen (Beijing) Outdoor Products Co., Ltd. to an associate company, which will no longer be included in the consolidated financial statements starting Q1 2024[18] Brand Performance - In Q1 2024, X-BIONIC achieved revenue of CNY 59.42 million, a year-on-year increase of 49.08%[18] - CRISPI generated revenue of CNY 20.62 million in Q1 2024, reflecting a year-on-year growth of 63.84%[18] Other Information - The number of ordinary shareholders at the end of the reporting period was 22,061[15] - The first quarter report for Beijing Sanfu Outdoor Products Co., Ltd. is unaudited[28] - The report was presented by the board of directors on April 30, 2024[29]
三夫户外(002780) - 2024 Q1 - 季度财报